Rapport Therapeutics announced a public offering of 9,615,385 shares of common stock at $26.00 per share, expecting to raise approximately $250 million. The offering is expected to close on September 11, 2025, with Goldman Sachs, Jefferies, TD Cowen, and Stifel acting as joint book-running managers.

Analysts are bullish on several little-known biopharma stocks, including Kymera Therapeutics, Vera Therapeutics, and Rapport Therapeutics, due to promising drug candidates and strong financial positions.

Rapport Therapeutics announced that its Phase 2a trial of RAP-219 for refractory focal epilepsy is fully enrolled and on track to report topline results in September 2025. The company also provided updates on the RAP-219 development program and its financial position.

Rapport Therapeutics, a clinical-stage biotechnology company, announced two encore poster presentations at the 2025 AAN Annual Meeting. The presentations will highlight the company's ongoing research and development of RAP-219, a clinical-stage AMPA receptor negative allosteric modulator, for the treatment of refractory focal epilepsy.

Rapport Therapeutics announced positive results from its Phase 1 trials for RAP-219, a potential treatment for central nervous system disorders. The data showed that RAP-219 achieved target receptor occupancy and was generally well-tolerated, supporting its ongoing Phase 2a trial in focal epilepsy.

Rapport Therapeutics, a clinical-stage biotechnology company, announced that it will present on its lead product candidate RAP-219 at two upcoming medical conferences focused on epilepsy. The presentations will cover the novel design of a Phase 2a proof-of-concept trial for RAP-219 in patients with drug-resistant focal epilepsy, as well as the underlying mechanism of action.

Rapport Therapeutics, a clinical-stage biotechnology company, announced that it will present at the Morgan Stanley Global Healthcare Conference and the TD Cowen's Novel Mechanisms in Neuropsychiatry Summit. The company is focused on developing small molecule medicines for central nervous system disorders.

Stay up to date on Wall Street news with our daily podcast available on Seeking Alpha, iTunes, and Spotify.

BOSTON and SAN DIEGO, June 12, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders, today announced the closing of its initial public offering of 9,200,000 shares of its common stock at a public offering price of $17.00 per share, which includes 1,200,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock in the offering. Rapport’s shares began trading on the Nasdaq Global Market on June 7, 2024, under the ticker symbol “RAPP.” All of the shares of common stock were sold by Rapport.